Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by longrun86on May 12, 2022 5:31pm
108 Views
Post# 34679560

RE:Pretty, pretty GUD...

RE:Pretty, pretty GUD...I am still digesting some of the more intricate details but my view is mixed on the Q1.
  • Revenue: Great to see this coming in ahead of expectations. This was a big positive for me.
  • Gross Margin: I am happy with this but think there is room to run by a few more percentage points on GM %.
  • Operating Income: This is still below where it should be relative to the investment that was made to acquire Biotoscana. There is still some work to be done in this area. Fortunately, the platform is already built so incremental revenue should come with a higher marginal rate of return. It is clear to me that Knight intends to do something material or their restructurng efforts would have brought down the G&A expenses further.
  • Integration: It was good to get an update that this has materially progressed. System changes and implementaiton are way harder than people ever think.
  • Investments: No surprise here. There will be further unrealized losses in Q2. I would like to see a timeline as to when they will wind down this component of the business as no longer appears to be a strategic priority and is now a potential impediment to the capital allocation priorities of Knight.
  • Buybacks: This reminds me of the Teledyne playbook from back in the 70's. I am happy to see them continue to buy at these levels.

This is a slow and steady team and that is fine by me.

Best of luck,

LR

<< Previous
Bullboard Posts
Next >>